| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:(-)-Bicuculline MethobroMide;[R-(R*,S*)]-5-(6,8-Dihydro-8-oxofuro[3,4-e]-1,3-benzodioxol-6-yl)-5,6,7,8-tetrahydro-6,6-diMethyl-1,3-dioxolo[4,5-g]isoquinoliniuMbroMide
CAS:73604-30-5
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
|
| | (-)-BICUCULLINE METHOBROMIDE Basic information |
| Product Name: | (-)-BICUCULLINE METHOBROMIDE | | Synonyms: | [R-(R*,S*)]-5-(6,8-DIHYDRO-8-OXOFURO[3,4-E]-1,3-BENZODIOXOL-6-YL)-5,6,7,8-TETRAHYDRO-6,6-DIMETHYL-1,3-DIOXOLO[4,5-G]ISOQUINDINIUM BROMIDE;[R-(R*,S*)]-5-(6,8-DIHYDRO-8-OXOFURO[3,4-E]-1,3-BENZODIOXOL-6-YL)-5,6,7,8-TETRAHYDRO-6,6-DIMETHYL-1,3-DIOXOLO[4,5-G]ISOQUINOLINIUM BROMIDE;(-)-BICUCULLINE 1(S),9(R) METHBROMIDE;(-)-BICUCULLINE METHOBROMIDE;Bicuculineracemic;(R-(R*,S*))-5-(6,8-Dihydro-8-oxofuro[3.4-e]-1,3-benzodioxol-6-yl)-5,6,7,8-tetrahydro-6,6-dimethyl-1,3-dioxolo[4.5-g]isoq;Bicuculinemethoiodide;[R-(R,S)]-5-(6,8-Dihydro-8-oxofuro[3,4-e]-1,3-benzodioxol-6-yl)-5,6,7,8-tetrahydro-6,6-dimethyl-1,3-dioxolo[4,5-g]isoquinolinium bromide | | CAS: | 73604-30-5 | | MF: | C21H20NO6.Br | | MW: | 462.29 | | EINECS: | | | Product Categories: | GABA;GABA/Glycine receptor | | Mol File: | 73604-30-5.mol |  |
| | (-)-BICUCULLINE METHOBROMIDE Chemical Properties |
| storage temp. | 2-8°C | | solubility | aqueous base: unstable | | form | solid | | color | white | | Water Solubility | Soluble in water (50mM) | | Sensitive | Light Sensitive |
| Safety Statements | 24/25 | | RIDADR | UN 1544 6.1/PG 2 | | WGK Germany | 3 | | HazardClass | 6.1(b) | | PackingGroup | III |
| | (-)-BICUCULLINE METHOBROMIDE Usage And Synthesis |
| Uses | (-)-Bicuculline methobromide is an N-methylated derivative of the GABAA?antagonist bicuculline. | | Biological Activity | Methobromide salt of (+)-bicuculline ([R-(R*,S*)]-6-(5,6,7,8-Tetrahydro-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)furo[3,4-e]-1,3-benzodioxol-8(6H)-one ). Water soluble and more stable than bicuculline. Non-GABA receptor-mediated actions reported. | | in vivo | (-)-Bicuculline methobromide can be used in animal modeling to create epilepsy models and is capable of crossing the blood-brain barrier[3].
1. Induction of epilepsy[3] Background
(-)-Bisculline methoromide can inhibit the synthesis and release of GABA, and weaken GABA's inhibition of neuronal activity in the SN reticular region (SNr), leading to epilepsy.
Specific Mmodeling Methods
Rat: Sprague-Dawley (SD) ? male or female ? 2 weeks old
Administration: 12.5, 25, 50 or 100 ng/0.25 μL ? inject into SN or corpus striatum through bilateral catheter implantation
Note
(1) Dissolve (-)-Bicuculine methoromide in distilled water and administer at a volume of 0.25 μL.
(2) Simultaneously administer bilateral infusions at a rate of 0.25 μ L/min, and after the infusion is completed, insert the catheter in situ for an additional minute to prevent drug reflux.
(3) Due to the short-lived effect of (-) - Bicuculine methoromide in SN, rats were tested 5 minutes after completing the infusion.
Modeling Indicators Behavioral observation: Shortened the latency period of epileptic seizures, causing stereotyped behaviors such as excessive sniffing or licking, chewing movements, head twitching, and slow or occasional circling.
Correlated Product(s): Muscimol (HY-N2313) Opposite Product(s): / | Animal Model: | Rat L5-SNL model[2] | | Dosage: | 0.6 nmol/rat | | Administration: | Intrathecal injection, 5 minutes before administration of Neurotropin (100 NU/kg, i.v.) | | Result: | Attenuated the antiallodynic effect of Neurotropin. |
| | storage | Room temperature |
| | (-)-BICUCULLINE METHOBROMIDE Preparation Products And Raw materials |
|